Ikena Oncology Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Ikena Oncology Stock Summary

Ikena Oncology competes with Edgewise Therapeutics, Design Therapeutics, Xilio Development, Eliem Therapeutics, and Monte Rosa. Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Ikena Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.

Ikena Oncology Key Financial Ratios

Ikena Oncology Key Balance Sheet Accounts

Ikena Oncology Key Cash Accounts

Ikena Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Ikena Oncology's current stock value. Our valuation model uses many indicators to compare Ikena Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ikena Oncology competition to find correlations between indicators driving Ikena Oncology's intrinsic value. More Info.Ikena Oncology is rated fifth overall in return on equity category among its peers. It also is rated fifth overall in return on asset category among its peers . At present, Ikena Oncology's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ikena Oncology's earnings, one of the primary drivers of an investment's value.

Ikena Oncology Systematic Risk

Today, most investors in Ikena Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ikena Oncology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Ikena Oncology growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Ikena Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ikena Oncology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ikena Oncology based on widely used predictive technical indicators. In general, we focus on analyzing Ikena Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ikena Oncology's daily price indicators and compare them against related drivers.

When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.